Outcome of transarterial chemoembolization monotherapy, and in combination with percutaneous ethanol injection, or radiofrequency ablation therapy for hepatocellular carcinoma

Hepatology Research

Volumn 39, Issue 6, 2009, Pages 553-562

  Kirikoshi, Hiroyuki ^a   Saito, Satoru ^a   Yoneda, Masato ^a   Fujita, Koji ^a   Mawatari, Hironori ^a   Uchiyama, Takashi ^a   Higurashi, Takuma ^a   Goto, Ayumu ^a   Takahashi, Hirokazu ^a   Abe, Yasunobu ^a   Inamori, Masahiko ^a   Kobayashi, Noritoshi ^a   Kubota, Kensuke ^a   Sakaguchi, Takashi ^a   Ueno, Norio ^a   Nakajima, Atsushi ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Combined therapy; Hepatocellular carcinoma; Milan criteria; Percutaneous ethanol injection; Radiofrequency ablation; Transarterial chemoembolization

Indexed keywords

ALCOHOL; EPIRUBICIN; GELATIN SPONGE; GELPART; IODINATED POPPYSEED OIL; UNCLASSIFIED DRUG;

ACUTE CHOLECYSTITIS; AGED; ARTICLE; BACTERIAL INFECTION; BILOMA; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CONTROLLED STUDY; DISTANT METASTASIS; ESOPHAGUS VARICES; FEMALE; HEMOPERITONEUM; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 66449106902     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2009.00490.x     Document Type: Article

References (32)

1. Xavier Bosch F. Global epidemiology of hepatocellular carcinoma. In: Okuda K, Tabor E, eds. Liver Cancer. New York: Churchill Livingstone, 1997; 13-28.
2. Wanebo HJ, Falkson G, Order SE. Cancer of the hepatobiliary system. In: Devita VT Jr, Hellman S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology, 3rd edn. Philadelphia, PA: Lippincott, 1989; 836-74.
3. Omata M, Yoshida H Prevention and treatment of hepatocellular carcinoma. Liver Transpl 2004; 10 (Suppl): S111-114.
4. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: A prospective study of 251 patients. Hepatology 1995; 21: 650-5.
5. Bruix J. Treatment of hepatocellular carcinoma. Hepatology 1997; 25: 259-62.
6. Mor E, Kaspa RT, Sheiner P, Schwartz M. Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation. Ann Intern Med 1998; 129: 643-53.
7. Koike Y, Shiratori Y, Sato S et al. Risk factors for recurring hepatocellular carcinoma differ according to infected hepatitis virus-an analysis of 236 consecutive patients with a single lesion. Hepatology 2000; 32: 1216-23.
8. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-17.
9. Bruix J, Sala M, Llovet JM. Chemoembolization for Hepatocellular Carcinoma. Gastroenterology 2004; 127: S179-188.
10. Llovet JM, Bustamante J, Castells A etal. Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29: 62-7.
11. Omata M, Tateishi R, Haruhiko Y, Shiina S. Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: Ethanol injection therapy and radiofrequency ablation. Gastroenterology 2004; 127: S159-S166.
12. Lencioni R, Allgaier HP, Cioni D etal. Small hepatocellular carcinoma in cirrhosis: Randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003; 228: 235-40.
13. Allgaier HP, Deibert P, Olschewski M etal. Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection - a single center analysis including 132 patients. Int J Cancer 1998; 79: 601-5.
14. Seki T, Nonaka T, Kubota Y, Mizuno T, Sameshima Y. Ultrasonically guided percutaneous ethanol injection therapy for hepatocellular carcinoma. Am J Gastroenterol 1989; 84: 1400-7.
15. Shiina S, Tagawa K, Unuma T etal. Percutaneous ethanol injection therapy of hepatocellular carcinoma: Analysis of 77 patients. Am. J Roentgenol 1990; 155: 1221-6.
16. Becker G, Soezgen T, Olschewski M, Laubenberger J, Blum HE, Allgaier HP Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma. World J Gastroenterol 2005; 11: 6104-9.
17. Tanaka K, Nakamura S, Numata K et al. The long term efficacy of combined transcatheter arterial embolization and percutaneous ethanol injection in the treatment of patients with large hepatocellular carcinoma and cirrhosis. Cancer 1998; 82: 78-85.
18. Liver Cancer Study Group of Japan. General Rules for the Clinical and Pathological Study of Primary Liver Cancer, 2nd English edn. Tokyo: Kanehara, 2003.
19. Kudo M, Chung H, Haji S etal. Validation of a new prognostic staging system for hepatocellular carcinoma: The JIS score compared with the CLIP score. Hepatology 2004; 40: 1396-405.
20. Llovet JM, Real MI, Montana X etal. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomized controlled trial. Lancet 2002; 359: 1734-9.
21. Lo CM, Ngan H, Tso WK etal. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-71.
22. Jansen MC, van Hillegersberg R, Chamuleau RA, van Delden OM, Gouma DJ, van Gulik TM. Outcome of regional and local ablative therapies for hepatocellular carcinoma: A collective review. EJSO 2005; 31: 331-47.
23. Nakamura H, Liu T, Hori S etal. Response to transcatheter oily chemoembolization in hepatocellular carcinoma 3cm or less: A study in 50 patients who underwent surgery. Hepato-gastroenterol 1993; 40: 6-9.
24. Koda M, Murawaki Y, Mitsuda A etal. Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma. A randomized control study. Cancer 2001; 92: 1516-24.
25. Veltri A, Moretto P, Doriguzzi A, Pagano E, Carrara G, Gandini G. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). Eur Radiol 2006; 16: 661-9.
26. Qian J, Feng GS, Vogl T. Combined interventional therapies of hepatocellular carcinoma. World J Gastroenterol 2003; 9: 1885-91.
27. Greten TF, Papendorf F, Bleck JS etal. Survival rate in patients with hepatocellular carcinoma: A retrospective analysis of 389 patients. Br J Cancer 2005; 92: 1862-8.
28. Kamada K, Kitamoto M, Aikata H et al. Combination of transcatheter arterial chemoembolization using cisplatin-lipiodol suspension and percutaneous ethanol injection for treatment of advanced small hepatocellular carcinoma. Am J Surg 2002; 184: 284-90.
29. Bartolozzi C, Lencioni R, Caramella D etal. Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. Radiology 1995; 197: 812-18.
30. Liem MS, Poon RT, Lo CM, Tso WK, Fan ST. Outcome of transarterial chemoembolization in patients with inoperable hepatocellular carcinoma eligible for radiofrequency ablation. World J Gastroenterol 2005; 11: 4465-71.
31. Liao GS, Yu CY, Shih ML et al. Radiofrequency ablation after transarterial embolization as therapy for patients with unresectable hepatocellular carcinoma. EJSO 2008; 34: 61-6.
32. Akamatsu M, Yoshida H, Obi S et al. Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: A randomized controlled trial. Liver Int 2004; 24: 625-30.